<?xml version="1.0" encoding="UTF-8"?>
<p>Considering this scenario, the evolution of the vaccine development against VL was relatively rapid. While no licensed vaccine against human Malaria is currently available, in spite of being a disease described in the fifth century BCE, four licensed veterinary vaccines are available against VL, a disease known only since 1903. Besides these veterinary vaccines, there is one live human Leishmania vaccine licensed in Uzbekistan (
 <xref rid="B78" ref-type="bibr">78</xref>). In fact, a mixture of live and dead 
 <italic>L</italic>. (L.) 
 <italic>major</italic> parasites has been licensed for leishmanization in areas with high-risk populations. The leishmanization technique was developed by Professor Adler, and this live vaccine was exhaustively used in Israel (
 <xref rid="B9" ref-type="bibr">9</xref>, 
 <xref rid="B78" ref-type="bibr">78</xref>). Although most field studies focus on human cutaneous leishmaniasis (CL), there have been no clinical trials of first-generation vaccines using species of 
 <italic>Leishmania</italic> causing VL (
 <xref rid="B79" ref-type="bibr">79</xref>).
</p>
